ArticleFrontiers in medicine2026
Baseline CALLY index is associated with all-cause mortality in HBV-ACLF patients receiving ALSS therapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic hepatitis B virus (HBV)-associated acute-on-chronic liver failure (HBV-ACLF) has a high mortality rate even with the use of artificial liver support systems (ALSS). Reliable prognostic biomarkers are lacking. This study investigates the association between the C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index, measured at diagnosis, and all-cause mortality in HBV-ACLF patients receiving ALSS treatment. Methods: This single-center retrospective cohort study enrolled consecutive adult patients with HBV-ACLF who received ALSS therapy at the General Hospital of Ningxia Medical University between May 2022 and November 2025. Baseline CALLY was calculated before ALSS initiation. Restricted cubic spline analysis, Kaplan-Meier survival analysis, and Cox regression were used to evaluate the association between CALLY and all-cause mortality. Logistic regression was used to assess its associations with major complications. Time-dependent ROC curves, Brier scores, calibration curves, and decision curve analysis were applied to evaluate the predictive performance and clinical utility of CALLY alone and in combination with conventional prognostic scores. Results: A total of 221 patients with HBV-ACLF were included, among whom 99 experienced all-cause mortality during follow-up. Patients with low CALLY had more severe systemic inflammation, poorer nutritional and immune status, higher proportions of hepatic encephalopathy and renal insufficiency, and more advanced disease severity than those with high CALLY. Restricted cubic spline analysis showed a significant nonlinear inverse association between baseline CALLY and all-cause mortality risk. Kaplan-Meier analysis demonstrated significantly better overall survival in the high-CALLY group than in the low-CALLY group (log-rank Conclusion: The baseline CALLY index was inversely associated with all-cause mortality in HBV-ACLF patients receiving ALSS therapy and may enhance prognostic assessment, especially when integrated with conventional prognostic scoring systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.